DWA
STRO icon

Dorsey Wright & Associates’s Sutro Biopharma STRO Stock Holding History

Dorsey Wright & Associates’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-183
Closed -$41.7K – 352
2021
Q1 		$41.7K Buy
183
+105
+135% +$24.9K 0.49% 86
2020
Q4 		$17K Buy
+78
New +$12.9K ﹤0.01% 198

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Dorsey Wright & Associates's STRO Position: Q2 2021 in Review

Dorsey Wright & Associates sold out of Sutro Biopharma (STRO) in Q2 2021, closing a stake of 183 shares — an estimated $41.7K sold.

Dorsey Wright & Associates first reported a position in STRO in Q4 2020 and held it in 2 quarters. The position peaked at $41.7K in Q1 2021. 124 funds tracked by Wall St. Rank hold STRO as of Q2 2021.

  • Dorsey Wright & Associates reported no remaining Sutro Biopharma position as of Q2 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 183 Sutro Biopharma shares in Q2 2021, an estimated $41.7K.
  • Dorsey Wright & Associates first reported a position in Sutro Biopharma in Q4 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's Sutro Biopharma position peaked at $41.7K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2021.

Based on Dorsey Wright & Associates's 13F filing for Q2 2021, filed 23 Jul 2021.